Alnylam Pharma (ALNY) AI Stock Analysis

• Market Cap: $40.72B
• Dividend Yield: N/A
• Average Volume (3M): 885.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 17.21%
• EPS Growth: 21.16%
• Country: US
• Employees: 2,230
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 130,388,400
• 10 Day Avg. Volume: 681,666
• 30 Day Avg. Volume: 885,198
• PEG Ratio: -0.88
• Price to Book (P/B): -182.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -47.15
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 3.25
• Enterprise Value/Gross Profit: 14.54
• Enterprise Value/Ebitda: -86.87
• 1Y Price Target: $328.41
• Price Target Upside: 5.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23

• Rating: 66 Neutral
• Price Target: $337.00 ▲(7.90%Upside)

Alnylam Pharma's overall score reflects a promising growth trajectory with strong technical indicators and strategic corporate actions. However, the high financial leverage and negative earnings impact the valuation, while the positive earnings call sentiment and corporate event developments highlight potential for future improvement.

Positive Factors

Market Potential

The company estimates there are as many as 100k patients with TTR-CM in Europe, which indicates a large potential market.

Product Launch

The Amvuttra launch in TTR-CM is anticipated to be the key value driver for Alnylam shares, with the majority of sales expected from the US.

Regulatory Approval

FDA approved Amvuttra for TTR-CM to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits, setting it apart from other treatments.

Negative Factors

Competitive Risks

Alnylam will present its Ph3 TRITON-CM trial design for nucresiran in ATTR-CM, which can be dosed half as frequently as Amvuttra.

Market Competition

The enrolled population of patients were receiving robust background therapy, including TTR stabilizers like Pfizer’s tafamidis and SGLT2 inhibitors.

Market Dynamics

Alnylam reported additional data for Amvuttra indicating strong effects in reducing all-cause mortality and cardiovascular mortality in the Ph3 HELIOS-B trial, yet competition from established TTR stabilizers remains.

Alnylam Pharma Business Overview & Revenue Model

Company Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Alnylam Pharmaceuticals generates revenue primarily through the sale of its RNAi-based therapeutic products. The company earns money from product sales, particularly from its commercialized medicines such as ONPATTRO, GIVLAARI, and OXLUMO, which target specific genetic disorders. In addition to product sales, Alnylam also engages in strategic collaborations and partnerships with other pharmaceutical companies, which provide additional revenue streams through milestone payments, licensing fees, and royalties. These partnerships often involve the joint development and commercialization of RNAi therapeutics, leveraging Alnylam's technology platform and expertise in RNA interference.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma shows promising revenue growth but struggles with profitability and operational efficiency. The balance sheet reveals high leverage, posing financial risk, yet strong liquidity from cash reserves provides some stability. Cash flow challenges persist, despite positive financing activities. The company's trajectory suggests potential, but risks tied to profitability and leverage need to be addressed for sustainable growth.

Income Statement

The income statement reveals a mixed performance for Alnylam Pharma. Despite a substantial revenue growth from $1.03 billion in 2022 to $2.35 billion TTM, the company continues to operate at a net loss, with a net profit margin of -11.49% TTM. Gross profit margin remains strong at 89.04% TTM, indicating efficient cost management. However, negative EBIT and EBITDA margins of -4.91% and -6.22% respectively, highlight ongoing operational challenges. While revenue growth is promising, the lack of profitability is a concern.

Balance Sheet

Alnylam Pharma's balance sheet shows a high level of debt relative to equity, with a debt-to-equity ratio of 11.27 TTM, indicating significant leverage. The return on equity (ROE) remains negative due to ongoing losses. However, the equity ratio is 2.74% TTM, which is positive but still reflects a weak equity position. The company's high level of cash and short-term investments is a positive aspect, providing liquidity support.

Cash Flow

The cash flow statement highlights some positive trends, with a significant financing cash flow of $309.33 million TTM, bolstering liquidity. However, both operating cash flow and free cash flow remain negative, indicating ongoing cash burn from operations and capital expenditures. The operating cash flow to net income ratio is negative, further emphasizing cash flow challenges despite a minor improvement in free cash flow growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.35B	2.25B	1.83B	1.04B	844.29M	492.85M
	Gross Profit
2.02B	1.92B	1.52B	868.60M	704.14M	414.80M
	EBIT
-115.37M	-176.88M	-282.18M	-785.07M	-708.65M	-828.44M
	EBITDA
-152.67M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
	Net Income Common Stockholders
-269.70M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.63B	2.69B	2.44B	2.19B	2.44B	1.87B
	Total Assets
4.21B	4.30B	3.83B	3.55B	3.64B	3.41B
	Total Debt
1.30B	1.30B	2.68B	1.32B	997.59M	521.19M
	Net Debt
281.98M	329.62M	1.87B	453.85M	177.62M	24.61M
	Total Liabilities
4.10B	4.17B	4.05B	3.70B	3.06B	2.39B
	Stockholders Equity
115.44M	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow		Free Cash Flow
-75.39M	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
	Operating Cash Flow
-45.11M	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
	Investing Cash Flow
64.55M	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
	Financing Cash Flow
309.33M	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 312.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Positive. The current price of 312.32 is above the 20-day moving average (MA) of 300.81, above the 50-day MA of 273.31, and above the 200-day MA of 263.72, indicating a bullish trend. The MACD of 9.37 indicates Positive momentum. The RSI at 66.75 is Neutral, neither overbought nor oversold. The STOCH value of 85.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALNY.

Alnylam Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	76 Outperform	$13.16B	11.64	19.94%	―	19.85%	21.16%
RPRX	74 Outperform	$19.63B	14.24	16.57%	2.52%	1.15%	37.75%
ARGX	68 Neutral	$33.07B	38.73	17.33%	―	78.01%	―
ALNY	66 Neutral	$40.72B	―	-414.62%	―	17.21%	21.16%
BNTX	61 Neutral	$25.23B	―	-3.87%	―	0.58%	-764.64%
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
SMMT	53 Neutral	$14.74B	―	-123.93%	―	―	-99.70%

Alnylam Pharma Corporate Events

Alnylam Pharma Appoints New Chief R&D Officer

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Alnylam Pharma Re-elects Directors at Annual Meeting

On March 10, 2025, Alnylam Pharma held its Annual Meeting where stockholders re-elected four Class III directors to serve until 2028. Additionally, stockholders approved several key proposals, including a Certificate of Amendment, the Second Amended and Restated 2018 Stock Incentive Plan, and the compensation of named executive officers. PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.